# kechowpharma

**Canonical:** https://apis.io/providers/kechowpharma/  
**Website:** https://kechowpharma.com  
**APIs profiled:** 0

Kechow Pharma (Shanghai Kezhou Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Shanghai's Zhangjiang High-Tech Park. It focuses on innovative small-molecule drug research and development in oncology and free-radical-related diseases, pursuing Best-in-Class therapeutics based on independent intellectual property. Its lead approved product is Kelopin (tolametinib), a MEK inhibitor for advanced NRAS-mutant melanoma. Surfaced as a portfolio company of Qiming Venture Partners; no public developer or API surface was found during enrichment.

## Kin Score — 3.3 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 3.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Kechowpharma Domain Security** — TLSv1.3

## Tags

Company, Pharmaceuticals, Biopharmaceutical, Oncology, Drug Development, Small Molecule, Clinical Stage, China

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/kechowpharma/). Scores are computed from the provider's own public artifacts under a published rubric.